SYRE Q1 2022 Earnings — Spyre Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

SYRESpyre Therapeutics, Inc.

$3B

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M

Gross Profit

$865,00063.5% margin

Operating Income

-$24M-1794.5% margin

Net Income

-$24M-1794.1% margin

EPS (Diluted)

$-9.26

QoQ Revenue Growth

-62.6%

Cash Flow

Operating Cash Flow

-$26M

Free Cash Flow

-$26M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$83M

Total Liabilities

$22M

Stockholders' Equity

$62M

Cash & Equivalents

$15M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$0	—
Gross Profit	$865,000	$0	—
Operating Income	-$24M	-$18M	-34.2%
Net Income	-$24M	-$18M	-34.1%